Sort
48,018 grants matching “immunotherapy”
Novel Stem Cell Immunotherapy for MDR-Tuberculosis
$958,345Chinnaswamy Jagannath · Methodist Hospital Research Institute · R01 · FY2024 · AI
Phase 1 cross over biodistribution study of [203Pb]VMT01 for single photon emission computed tomography (SPECT) and [68Ga]VMT02 for positron emission tomography (PET) imaging of stage 4 melanoma
$958,108Frances L Johnson · Viewpoint Molecular Targeting, Inc. · R44 · FY2019 · CA
PEDIATRIC AIDS CLINICAL TRIALS GROUP
$958,057Columbia University Health Sciences · U01 · FY2001 · AI
Integrated analysis of HBV-specific CD4 T cell and B cell responses to define their role in chronic hepatitis B and HBV functional cure.
$957,683Georg Michael Lauer · Massachusetts General Hospital · R01 · FY2025 · AI
Ultrasound-based diagnostic and monitoring of bladder cancer treatment with drug released from nanoparticles
$956,875Joe Assouline · Nanomedtrix, Llc · R44 · FY2022 · CA
Elucidating and Targeting tumor dependencies and drug resistance determinants at the single cell level
$956,166Andrea Califano · Columbia University Health Sciences · U01 · FY2023 · CA
Targeting LIF/LIFR in pancreatic cancer
$956,072Hareesh Babu Nair · Evestra, Inc. · R44 · FY2021 · CA
Basic Research Support for the CCR
$955,878Robert Wiltrout · Division Of Basic Sciences - Nci · ZIC · FY2012 · CA
Interaction between nuclear epigenetic and metabolic pathways in cancer
$955,500Shelley L Berger · University Of Pennsylvania · R35 · FY2023 · CA
Cyclic Flow Cytometry for Ultra-High Marker Single-Cell Analysis
$955,253Sheldon J.j. Kwok · Lase Innovation Inc. · R44 · FY2021 · GM
GMP MANUFACTURE OF CLINICAL GRADE THERAPEUTIC VACCINE FOR THE TREATMENT OF PATIENTS WITH CHRONIC HBV
$954,675Valerian Nakaar · Carogen Corporation · R44 · FY2022 · DK
Role of Tumor Stroma in Therapeutic Response and Resistance
$954,554Lynda Chin · University Of Tx Md Anderson Can Ctr · U54 · FY2013 · CA
PATHWAYS TO TOLERANCE IN HUMAN ISLET TRANSPLANTATION
$954,541University Of Miami School Of Medicine · R01 · FY2001 · DK
Human natural killer cells: Advancing biology and clinical applications
$954,486Michael A Caligiuri · Beckman Research Institute/City Of Hope · R35 · FY2023 · CA
Human natural killer cells: Advancing biology and clinical applications
$954,486Michael A Caligiuri · Beckman Research Institute/City Of Hope · R35 · FY2022 · CA
Biomarkers and Therapeutic Targets in Tumor Microenvironment and Metastasis
$954,297Rosandra Kaplan · Division Of Basic Sciences - Nci · ZIA · FY2021 · CA
Tissue Processing-Sequencing Facility
$954,130Cathy D Vocke · Division Of Basic Sciences - Nci · ZIC · FY2025 · CA
Validation of a Negative Regulator as a Novel Therapy for Autoimmune Disease
$954,097Jay L Rothstein · Immunext, Inc. · R42 · FY2015 · AI
The role of clonal hematopoiesis in the development and therapy of myeloid malignancies
$954,038Benjamin Levine Ebert · Dana-Farber Cancer Inst · R35 · FY2024 · CA
Molecular Pathogenesis of Neoplasia
$953,971John Heiss · National Institute Of Neurological Disorders And Stroke · ZIA · FY2023 · NS
RECURRENT HEPATITIS B AFTER LIVER TRANSPLANTATION
$953,315University Of Michigan At Ann Arbor · U01 · FY2004 · DK
Trinity: Transcriptome assembly for genetic and functional analysis of cancer
$953,262Eric Banks · Broad Institute, Inc. · U24 · FY2020 · CA
DEVELOPMENTAL FUNDS (Core 002)
$953,077Norman Edward Sharpless · Univ Of North Carolina Chapel Hill · P30 · FY2016 · CA
A Novel Immunological-Directed Biotherapy for Treating Rheumatoid Arthritis
$952,967Gary Fanger · Rise Therapeutics, Llc · R44 · FY2025 · AG
Mechanisms and Vulnerabilities of SWI/SNF chromatin remodeling complex mutant lung cancer
$952,822Yonathan Lissanu · University Of Tx Md Anderson Can Ctr · R37 · FY2025 · CA